2025 Drug Safety Communications
Current Drug Safety Communications More Drug Safety Communications
- 08-28-2025 FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)
- 08-27-2025 FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozapine
- 07-31-2025 FDA is requiring opioid pain medicine manufacturers to update prescribing information regarding long-term use
- 06-30-2025 FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD
- 06-18-2025 FDA adds warning about serious risk of heat-related complications with antinausea patch Transderm Scōp (scopolamine transdermal system)
- 05-16-2025 FDA requires warning about rare but severe itching after stopping long-term use of oral allergy medicines cetirizine or levocetirizine (Zyrtec, Xyzal, and other trade names)
- 01-22-2025 FDA adds Boxed Warning about a rare but serious allergic reaction called anaphylaxis with the multiple sclerosis medicine glatiramer acetate (Copaxone, Glatopa)